Most Down Articles

Published in last 1 year | In last 2 years| In last 3 years| All| Most Downloaded in Recent Month| Most Downloaded in Recent Year|

Most Downloaded in Recent Month

Please wait a minute...


For Selected: Download Citations EndNote Reference Manager ProCite BibTeX RefWorks Toggle Thumbnails

Select

Electronic Journal of Liver Tumor    2020, 7 (3): 43-45.   Abstract （73）      PDF （1519KB）（203）       Knowledge map    Save Related Articles | Metrics

Select

Electronic Journal of Liver Tumor    2020, 7 (4): 54-58.   Abstract （255）      PDF （2920KB）（306）       Knowledge map    Save Reference | Related Articles | Metrics

Select

Research progress on occupational stress formation of oncology nurses A-yun ZHAO, Jing-hui Li, Na Zhuang, Yun Liu Electronic Journal of Liver Tumor    2019, 6 (4): 36-38.   Abstract （168）   HTML （6）    PDF （1187KB）（501）       Knowledge map    Save At present, the incidence of cancer is increasing year by year, and oncology nurses also need to face more and more work pressure. Compared with nurses in general departments, oncology nurses should not only carry out necessary nursing for cancer patients, but also comprehensively master the medication, observation, nursing and psychological counseling for cancer patients. High-intensity work and persistent physical and mental burden not only affect the mental health status of nurses, but also reduce the quality of care. Therefore, from the perspective of occupational stress of nurses in hospital oncology department, this paper makes an in-depth analysis of the factors that affect the pressure of nurses in the daily nursing process, and puts forward corresponding improvement strategies, attaching importance to the professional management of nurses, effectively relieving the pressure of nurses, and promoting the sustainable and healthy development of their mental health and nursing quality. Reference | Related Articles | Metrics

Select

Electronic Journal of Liver Tumor    2024, 11 (3): 1-13.   Abstract （68）      PDF （1944KB）（406）       Knowledge map    Save Reference | Related Articles | Metrics

Select

Radiotherapy compared with palliative care for advanced hepatocellular carcinoma with portal vein tumor thrombus: using a new classification Yang Liu, Zhu Xiling, Jin Shuai, Chang Na, Zhao Yufei, Li Gong Electronic Journal of Liver Tumor    2020, 7 (3): 7-11.   Abstract （105）      PDF （1645KB）（134）       Knowledge map    Save Objective: To evaluate the efficiency of radiotherapy (RT) for unresectable hepatocellular carcinoma (HCC) with portal vein tumor thrombosis (PVTT) and the significance of Cheng's classification for the prognosis. Methods: A retrospective analysis was performed on 105 patients with HCC with PVTT in the Third Medical Center of PLA General Hospital from January 2010 to October 2016, among whom 67 underwent RT and 38 received palliative care. Survival analysis of the two treatment groups was performed with Kaplan-Meier and then stratified by Cheng’s classification of PVTT. And the prognostic factors were analyzed. Results: The median survival,1-year, 2-year and 5-year survival rate of RT group and palliative group was 9 vs. 3 months, 41.8% vs. 2.6%, 20.1% vs. 0, 4.5% vs. 0. On subgroup analysis of PVTT, the median survival in the RT group for type Ⅱ, Ⅲ, and Ⅳ PVTT was 13, 8, and 5 months, respectively. In RT group, the survival of type III was better than type IV (P = 0.044), but inferior to type II (P = 0.011). PVTT type, tumor number and RT dose were independent prognostic factors for survival (P = 0.041, P = 0.028, P = 0.015). Conclusions: Radiotherapy is an effective treatment compared with palliative care for HCC and PVTT, and Cheng's classification can initially provide a better prognosis evaluation for HCC with PVTT who underwent radiotherapy. Reference | Related Articles | Metrics

Select

Electronic Journal of Liver Tumor    2020, 7 (2): 2-11.   Abstract （233）      PDF （1680KB）（422）       Knowledge map    Save Reference | Related Articles | Metrics

Select

Research progress in immunotherapy and biomarkers for hepatocellular carcinoma Peng Xuenan, Zhou Aiping Electronic Journal of Liver Tumor    2020, 7 (4): 17-22.   Abstract （91）      PDF （1654KB）（411）       Knowledge map    Save The incidence of hepatocellular carcinoma (HCC) in China ranked fourth among all malignant tumors, and the mortality rate ranked second in 2015. Approximately 85% of Chinese patients are in the intermediate stage or advanced stage at the first visit and lose the best treatment chance. The 5-year survival rate of them is only 12%. Since 2007, treatments for advanced hepatocellular carcinoma mostly focused on targeted therapy, with limited efficacy. In recent years, immune checkpoint inhibitors have achieved 17% ~ 20% and 15% ~ 20% objective response rate in first-line and second-line monotherapy respectively. Immunotherapy shows obviously anti-tumor effect that is superior to traditional targeted therapy. Initial results have also achieved in the field of neoadjuvant and adjuvant therapy for HCC. However, several challenges such as treatment selection after disease progression and disease recurrence after liver transplantation are still unsolved. Exploring immune-specific biomarkers to predict the efficacy has also become an important direction in the field of immunotherapy. In this review, we summarized the research progress of immunotherapy and biomarkers for hepatocellular carcinoma. Reference | Related Articles | Metrics

Select

Establishment of a rat model: associating liver partition and portal vein ligation for staged hepatectomy with hepatic fibrosis Zhang Junwei, Yang Xu, Wang Yunchao, Wang Yanyu, Xun Ziyu, Cheng Quancheng, Fang Jinyu, Ding Huiru, Meng Jieyi, Zhang Lei, Xu Yiyao, Sang Xinting, Zhao Haitao, Zhang Weiguang, Lu Xin Electronic Journal of Liver Tumor    2022, 9 (2): 1-6.   Abstract （81）      PDF （5479KB）（54）       Knowledge map    Save Objective:To establish the liver fibrosis model of associating liver partition and portal vein ligation for staged hepatectomy (ALPPS) by carbon tetrachloride (CCl4) and ethanol, and to explore the feasibility and safety of ALPPS in rats with liver fibrosis. Method:Totally 40 male SD rats were randomly allocated by lot into two groups with 20 rats in each group. The control group was the blank group, which was routinely fed and injected with olive oil for 4 weeks, and the liver fibrosis group was CCl4 subcutaneous injection + forced drinking of 10% ethanol for 4 weeks. 5 rats in the liver fibrosis group and the control group were stained with Sirius red to judge the degree of liver fibrosis. The remaining 15 rats underwent ALPPS operation, and the regenerated liver was weighed on the 0, 3 and 6 days after operation to detect the liver proliferation, and was further judged by the hepatocyte regeneration by Ki-67 staining. Result:After 4 weeks of CCl4 and ethanol modeling, the weight of rats increased slowly, their life was basically unaffected, and liver fibrosis was uniform. One rat died due to the injection of CCl4, and the success rate of liver fibrosis modeling was 95.0%. Liver fibrosis group and control group achieved rapid growth of residual liver volume after ALPPS, and there was no significant difference between the two groups. Ki-67 positive cells in hepatic fibrosis group and normal group increased significantly on the 3rd day after operation and decreased on the 6th day after operation. Conclusion:Using the method of CCl4 back subcutaneous injection and drinking ethanol, the liver fibrosis rat model can be established quickly. ALPPS operation is safe and feasible in this fibrosis model. In this study, a stable and efficient ALPPS rat model with liver fibrosis was established. Reference | Related Articles | Metrics

Select

Electronic Journal of Liver Tumor    2020, 7 (3): 46-46.   Abstract （65）      PDF （1763KB）（55）       Knowledge map    Save Related Articles | Metrics

Select

Electronic Journal of Liver Tumor    2023, 10 (1): 49-52.   Abstract （50）      PDF （4204KB）（138）       Knowledge map    Save Reference | Related Articles | Metrics

Select

Clinical study on individualized medication of tacrolimus after liver transplantation guided by CYP3A5 gene polymorphism for hepatocellular carcinoma Jiang Tao, Pan Fei, Chen Qing, Huang Jincan, He Qiang, Lang Ren Electronic Journal of Liver Tumor    2021, 8 (3): 8-11.   Abstract （76）      PDF （1641KB）（185）       Knowledge map    Save Objective: To evaluate the safety and efficacy based on CYP3A5 gene polymorphisms in guiding the individualized tacrolimus therapy after liver transplantation for hepatocellular carcinoma. Methods: Clinical data of 120 patients with primary hepatocellular carcinoma were analyzed who underwent orthotopic liver transplantation from January 2018 to December 2019. According to whether the donor and recipient CYP3A5 gene was detected before operation, they were divided into individualized medication group and conventional medication group. The initial dose of tacrolimus was determined according to CYP3A5 genotype and previous experience in the two groups. The recovery rates of liver function at 14, 21, 28 days and 3, 6, 9, 12 months after operation were observed. The incidence of acute rejection, acute kidney injury, neurological symptoms, infection, de novo hypertension, de novo diabetes and the overall survival rate were recorded. Results: The differences of recovery rate of liver function between the two groups of recipients at 14 days and 21 days after was statistically significant (all P<0.05). There was no significant difference in the incidence of complications and overall 1-year and 2-year survival rates between the two groups (P> 0.05). Conclusion: It is safe to guide individualized tacrolimus after liver transplantation according to CYP3A5 gene polymorphism and beneficial to long-term survival for hepatocellular carcinoma recipients. Reference | Related Articles | Metrics

Select

Efficacy and safety of particle therapy for hepatocellular carcinoma: a meta-analysis Liu Ruifeng1, Wang Dandan2, Zhang Qiuning1, Luo Hongtao3, Dong Meng2, Wang Xiaohu1,* Electronic Journal of Liver Tumor    2022, 9 (4): 32-45.   Abstract （100）      PDF （4146KB）（35）       Knowledge map    Save Objective:To evaluate the efficacy and safety of proton and heavy ion therapy for hepatocellular carcinoma (HCC). Method:Medline, Embase, Web of Science, China Biology Medicine (CBM), Wanfang Database and China National Knowledge Internet (CNKI) were systematically searched from inception to July 2022. Two researchers independently screened the titles and abstracts, extracted the data, and evaluated the methodological quality of the included studies. STATA 14.0 software was used for meta-analysis. Result:Totally 13 proton irradiation and 8 carbon ion irradiation which included 1884 patients were included in our final research. The results of meta-analysis showed that carbon ion and proton irradiation could achieve higher long-term local control (LC) rates {5-year LC rate: 90% [95%(confidence interval, CI): 86%-94%], 85% (95%CI: 80%-91%)} and long-term overall survival (OS) rates for HCC [5-year OS rate: 33% (95%CI: 23%-43%), 41% (95%CI: 32%-50%)]. The results of subgroup analysis showed that HCC patients with small tumor diameter, Child-Pugh grade A, primary treatment and single tumor could achieve better survival outcomes, and the incidence of grade 3 or higher adverse events was low. Conclusion:Proton and heavy ion therapy offer high local control, acceptable overall survival and a low recurrence rate for HCC. However, the existing literature is of low quality and incomplete reporting, especially on toxicity. Therefore, there is a strong need for more prospective, multicenter, and high-quality studies. Reference | Related Articles | Metrics

Select

Effect of aryl hydrocarbon receptor gene knockout on metabolic pathways and metabolites in hepatocellular carcinoma Wei Zhewen, Zhu Qing, Cai Jianqiang Electronic Journal of Liver Tumor    2023, 10 (4): 23-28.   Abstract （82）      PDF （4069KB）（32）       Knowledge map    Save Objective:To investigate the effect of aryl hydrocarbon receptor (AHR) gene knockout on metabolic pathways and metabolites in hepatocellular carcinoma (HCC). Method:PLC/PRF/5 hepatoma cell line with AHR knockout was constructed by clustered regularly interspaced short palindromic repeats (CRISPR)/Cas9 technology. Untargeted metabolomics was performed on the wild type (AHR-WT) and AHR knockout (AHR-KO) hepatoma cells to detect the metabolites, and the differential metabolites between the two groups were analyzed. Metaboanalyst 4.0 was used to perform metabolic pathway enrichment analysis and find differential metabolites. Result:The AHR-WT and AHR-KO hepatoma cells were examined for metabolites under positive and negative ionic model respectively. The results showed that the top 10 functional enrichments were mainly amino acid metabolism glutamate metabolism, glycine and serine metabolism, arginine and proline metabolism, methionine metabolism, aspartate metabolism, urea cycle, ammonia recycling, energy metabolism glutathione metabolism, Warburg effect and nucleotide metabolism purine metabolism. The pathway enrichment analysis showed that eight metabolic pathways were found including arginine and proline metabolism, arginine biosynthesis, pyrimidine metabolism, alanine, aspartic acid and glutamate metabolism, phenylalanine, tyrosine and tryptophan biosynthesis, purine metabolism, lysine degradation, ascorbic acid and uronate metabolism. Compared with AHR-WT hepatoma cells, the levels of L-arginine, L-phenylalanine, L-tyrosine, uridine and xanthine were significantly down-regulated in AHR-KO hepatoma cells. Nicotinamide adenine dinucleotide (NADH), oxidized glutathione and nicotinamide adenine dinucleotide phosphate (NADPH) were significantly up-regulated in the AHR-KO cells. Conclusion:AHR may play an important role in the metabolism of HCC, and the research on the metabonomics of HCC by targeting AHR may be a new anti-tumor treatment strategy. Reference | Related Articles | Metrics

Select

Electronic Journal of Liver Tumor    2020, 7 (1): 51-53.   Abstract （128）      PDF （1598KB）（170）       Knowledge map    Save Related Articles | Metrics

Select

Electronic Journal of Liver Tumor    2020, 7 (1): 65-69.   Abstract （65）      PDF （2314KB）（214）       Knowledge map    Save Related Articles | Metrics

Select

Electronic Journal of Liver Tumor    2020, 7 (4): 52-53.   Abstract （65）      PDF （1880KB）（108）       Knowledge map    Save Related Articles | Metrics

Select

The mechanism of histone deacetylase inhibitor vorinostat inhibiting the growth of hepatocellular carcinoma cells Gu Xinglu, Zhao Xiaohang, Sun Yulin Electronic Journal of Liver Tumor    2023, 10 (1): 15-24.   Abstract （137）      PDF （9724KB）（82）       Knowledge map    Save Objective: To investigate the mechanism of exonuclease 1 (EXO1) in hepatocellular carcinoma (HCC) and the possible mechanism of the histone deacetylase (HDAC) inhibitor vorinostat inhibiting the growth of HCC cells. Methods: HCC cell lines with knockdown or overexpression of EXO1 were constructed. And the effects of EXO1 on the proliferation, migration and invasion in HCC were investigated by cell phenotype assays. The role of EXO1 in homologous recombination (HR) repair and its effect on ionizing radiation sensitivity of cells were detected by HR reportor assay, immunofluorescence and western blots. Additionally, HCC cells were treated with vorinostat. The effect of vorinostat on EXO1 expression and the possible mechanism of inhibiting the growth of HCC cells were detected by CCK-8, flow cytometry and Western blotting. Results: High level of EXO1 promoted the proliferation, migration and invasion of HCC cells. EXO1 also promoted DNA double-strand break repair through the HR pathway and reduced cell sensitivity to ionizing radiation. In addition, elevated EXO1 levels were less sensitive to vorinostat, whereas knockdown of EXO1 increased the sensitivity of hepatocellular carcinoma cells to vorinostat. Vorinostat further inhibited the HR repair ability of HCC cells by suppressing EXO1 expression, thereby inhibiting cell growth. Conclusion: Vorinostat can inhibit HR repair ability by decreasing the expression level of EXO1, which may serve as a potential therapeutic target for HCC Reference | Related Articles | Metrics

Select

Electronic Journal of Liver Tumor    2023, 10 (4): 72-76.   Abstract （53）      PDF （5346KB）（46）       Knowledge map    Save Reference | Related Articles | Metrics

Select

Electronic Journal of Liver Tumor    2020, 7 (3): 47-47.   Abstract （57）      PDF （1344KB）（65）       Knowledge map    Save Related Articles | Metrics

Select

Electronic Journal of Liver Tumor    2019, 6 (3): 22-23.   Abstract （202）   HTML （5）    PDF （864KB）（280）       Knowledge map    Save Table and Figures | Reference | Related Articles | Metrics